August 26, 2021 7:51am

Volatility sketches a contradictory picture of the short-term after extending a winning streak to five sessions on the S&P 500 and Nasdaq.

Pre-open indications: SELLs: 3; BUYs: 3; Maintain SELL: 3

If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing.

Never leave an investor uninformed!

Dow futures are UP +0.08% (+10 points), S&P futures are DOWN -0.04% (-2 point) and NASDAQ futures are DOWN -0.13% (-20 points)

 

S&P 500 futures were warbling lower in the pre-market on Thursday,

European shares were in decline following the global market mood,

Asia-Pacific stocks mostly struggled on Thursday, as U.S. stocks again surged to record highs.

 

Data Docket: The highly anticipated Jackson Hole symposium starts. Last week’s jobless claim data will be released at 8:30 a.m. ET; economists are expecting 350,000 Americans filed for unemployment last week, compared to the prior week’s 348,000.

 

Henry’omics:

How long do new record highs last – until they don’t!

The major indexes rose slightly but the S&P 500 and Nasdaq hit fresh all-time highs while the Dow Jones nudged closer to another record levels. The small-cap Russell 2000 reclaimed its 50-day moving average for the first time on July 12. <IBD>

And do you think that downdrafts just happen – they don’t!

 

If you didn’t know what happen at Wednesday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:

 

  • The Nasdaq closed UP +22.06 points (+0.15%)
  • The IBB closed up +0.67% and XBI closed up +1.10%
  • Sector volume was LOW with 2 of the 20-upside having higher than the 3-month average volume with very LOW volume of 3 of 13-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was down -0.43 points or -2.50% at 16.79
  • Wednesday’s percentage (%) of the 20-upside were +0.28% (AGTC) to +19.62% (BLFS) while the 13-downside -0.19% (RGNX) to -5.72% (BLCM);

 

  • Q3/21: August: 10 positive and 8 negative close
  • July: 6 positives, 1 holiday and 15 negative closes

Q2/21:

  • June: 15 positive and 8 negative closes
  • May:  8 positive, 12 negative closes and 1 holiday
  • April: 11 negative and 10 positive closes

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) Chronicles - Maintaining Sell – notice how the shares trade with the “pump/promote”?

Biostage (BSTG) closed up again +$0.16 with 18,472 shares traded after Tuesday’s +$0.28 with 10,590 shares traded after Monday’s +$0.68 to $1.89 with 38,354 shares traded, Friday’s -$0.07 to $1.21 with 570 shares traded and last Thursday’s flat with 50 shares traded.

Question#1: HOW did “this” all get started … is it related to past … VISAS which included INVESTMENT to get Chinese communist leaders and executive’s children into American schools and universities?

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.

 

Pre-open Indications:

BUY:

Ionis Pharmaceuticals (IONS) closed down -$0.44 after Tuesday’s +$0.95 following Monday’s -$0.23 and has positive +0.94 or +2.38% aftermarket indication,

Intellia therapeutics (NTLA) closed down -$3.86 after Tuesday’s +$4.26 and has a positive +$3.54 or +2.23% pre-market indication;

Pluristem (PSTI) closed down -$0.11 after Tuesday’s +$0.05 and has a positive +$0.03 or +1.01% pre-market indication;

 

SELL from BUY:

BioLife Solutions (BLFS) closed up +$9.19 after Tuesday’s -$0.27 and being named to the S&P SmallCap 600 Index effective prior to the opening of trading on Monday, August 30, 2021 and has a negative -$0.05 or -0.09% pre-market indication;

Sage Therapeutics (SAGE) closed up +$0.30 after Tuesday’s +$0.31 and has a negative -$0.58 or -1.33% aftermarket indication.

Voyager Therapeutics (VYGR) closed up +$0.06 and has a negative -$0.22 or -6.77% aftermarket indication,

 

Maintaining SELL:

CRISPR Therapeutics (CRSP) closed down -$0.66 after Tuesday’s +$1.44 and has a negative -$1.70 or -1.35% pre-market indication;

Editas Medicine (EDIT) closed up +$0.87 after Tuesday’s -0.64 and has a negative -$0.33 or -0.50% pre-market indication,

 

The BOTTOM LINE: August is a historically volatile month for markets and this year is no different, with investors currently climbing the walls of worries …

"Everything we hear is an opinion, not a fact. Everything we see is a perspective, not the truth." Marcus Aurelius.

  • Four (4) positive closes in a row, four (4) negative closes out of thee last ten (10) sessions,
  • The IBB is up +2.24% in three (3) sessions,
  • The XBI is up +5.70% in three (3) sessions,
  • Wednesday’s percentage (%) of the 20-upside were +0.28% (AGTC) to +19.62% (BLFS) while the 13-downside -0.19% (RGNX) to -5.72% (BLCM);
  • Tuesday’s percentage (%) of the 21-upside were +0.38% (VCEL) to +9.21% (BLCM) while the 12-downside -0.41% (RGNX) to -3.95% (PGEN);
  • Monday’s percentage (%) of the 32-upside were +0.31% (ALNY) to +56.20% (BSTG) while the 1-downside -0.59% (IONS);

The alternating cycle of being oversold is the ability to be overbought after multiple sessions and the … REVERT back.

When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started

Investors should take short-term profits to cash-up for coming drifts!

Some earnings’ Reports Outstanding:

  • Applied Genetic Technologies (AGTC), Mesoblast (MESO), Pluristem (PSTI) and Pluristem (PSTI), ReNeuron (RENE.L)

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.